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AbstrACt
Introduction Observational data suggest that vitamin D 
deficiency is associated with the onset and progression of 
knee osteoarthritis (OA). However, randomised controlled 
trials (RCTs) to date investigating the efficacy of vitamin 
D supplementation in knee OA have reported conflicting 
results. Further research is needed to clarify the effects 
of vitamin D on patient- reported outcomes and determine 
whether there are patient subgroups who may benefit from 
the supplementation. The aim of this individual patient data 
(IPD) meta- analysis is to identify patient- level predictors of 
treatment response to vitamin D supplementation on pain 
and physical function.
Methods and analysis A systematic literature search 
will be conducted for RCTs of vitamin D supplementation 
on knee OA. Authors of original RCTs will be contacted to 
obtain the IPD. The primary outcomes will include long- 
term (≥12 months) pain and physical function. Secondary 
outcomes will include medium- term (≥6 months and <12 
months) and short- term (<6 months) pain and physical 
function, as well as patient global assessment, quality 
of life and adverse events. Potential treatment effect 
modifiers to be examined in the subgroup analyses 
include age, gender, body mass index, baseline knee pain 
severity and physical function, baseline vitamin D level, 
radiographic stage, presence of bone marrow lesions on 
MRI, presence of clinical signs of local inflammation and 
concomitant depressive symptoms. Both one- step and 
two- step modelling methods will be used to determine the 
possible modifiable effect of each subgroup of interest.
Ethics and dissemination Research ethical or 
governance approval is exempt for this study as no 
new data are being collected. This study will be the 
first IPD meta- analysis to clarify the effect of vitamin 
D supplementation on clinical symptoms in different 
subgroups of patients with knee OA. The findings will 
be disseminated through peer- review publications and 
conference presentations.
PrOsPErO registration number CRD42018107740.
IntrOduCtIOn
Osteoarthritis (OA) is the most common joint 
disorder worldwide. OA is ranked as the 13th 
highest contributor of 310 diseases to global 
disability in 2015.1 In Australia, OA affects 
over 2.1 million people (9% of the popu-
lation), costing the healthcare system over 
$2.1 billion in 2015.2 This cost is forecasted to 
increase by 39% in 2030.3
The majority (83%) of the disease burden 
of OA is attributable to knee OA,4 which is 
characterised by pain, gradual loss of artic-
ular cartilage and structural changes such 
as subchondral remodelling and effusion- 
synovitis.5 Currently, there are no effective 
disease- modifying treatments to reverse the 
progression of knee OA once the disease is 
established. A majority of patients with knee 
OA eventually progress to advanced stage 
strengths and limitations of this study
 ► This study protocol is endorsed by the osteoarthritis 
(OA) Trial Bank, an international collaboration that 
initiates meta- analyses on predefined subgroups of 
OA patients.
 ► This study is the first individual patient data (IPD) 
meta- analysis to identify OA patient subgroups that 
may benefit from vitamin D supplementation.
 ► IPD meta- analysis offers greater statistical power 
and precision than subgroup analysis in a single tri-
al and conventional meta- analysis using aggregate 
data.
 ► Analysis may be limited to the variables that have 
been collected across included randomised con-
trolled trials.
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and undergo total knee replacement.6 There is clearly an 
urgent need for innovative and cost- effective approaches 
to slow the progression of knee OA.
Emerging observational data suggest that vitamin D 
insufficiency is associated with the onset and progression 
of knee OA.7 The association between low serum vitamin 
D levels and knee OA symptoms may be explained by a 
direct effect of vitamin D on chondrocytes in osteoar-
thritic cartilage,8 as well as indirect effects on subchon-
dral bone, synovium and periarticular muscle.9 For 
example, vitamin D deficiency could impair the ability of 
bone to respond optimally to pathological bone marrow 
lesions (BMLs) and altered bone mineral density, there-
fore predisposing the knees to disease progression.10 
Vitamin D also may reduce synovitis in affected knees 
by regulating cytokine levels in the joint, leading to a 
reduction in the amount of effusion- synovitis in MRI.11 
In addition, depressive symptoms is interrelated to joint 
pain in OA,12 and maintaining sufficient serum vitamin 
D may improve depression symptoms in patients with 
knee OA.13
However, evidence from randomised controlled trials 
(RCTs) have been conflicting.14–17 A pilot RCT in India 
found a small but statistically significant clinical benefit 
for 12- month vitamin D treatment on pain and function 
in patients with knee OA, compared with placebo.16 In 
contrast, a subsequent RCT from the USA showed that 
vitamin D supplementation did not reduce knee pain 
or cartilage volume loss over 24 months.15 Subsequently, 
data from RCTs in Australia17 and UK14 did not find 
significant clinical benefits of vitamin D supplementa-
tion for knee OA. However, there was a non- significant 
trend for symptom reduction (eg, knee pain and phys-
ical function) in these RCTs. Two systematic reviews 
using aggregate data from these RCTs concluded that, 
although current evidence does not support vitamin D 
supplementation for reducing structural disease progres-
sion, further research is needed to clarify the effects on 
patient- reported outcomes.18 19 In addition, to the best of 
our knowledge, no previous systematic reviews of previous 
systematic reviews exist.
The null results of these RCTs could be due to a low 
prevalence of vitamin D deficiency in the study subjects 
or low statistical power secondary to small sample sizes. 
Another possible reason is that vitamin D may have an 
effect only in some OA phenotypes, such as those with 
BMLs (predominant bone abnormality),20 effusion- 
synovitis (inflammatory)21 or depressive symptoms 
(psychological distress).13 Post hoc analyses within 
these RCTs15 21 were frequently underpowered, and 
hence unreliable to determine the effect of vitamin D 
treatment on subgroups of knee OA patients. A meta- 
analysis using individual patient data (IPD) can increase 
the power of subgroup analysis by combining individual 
data from included trials22 and therefore can quantify 
potential effect modifier of vitamin D treatment in 
subgroups.
MEthOds And AnAlysIs
We will conduct a systematic review and IPD meta- analysis 
of RCTs studying the effects of vitamin D supplementa-
tion in patients with symptomatic knee OA. The primary 
aim is to identify patient- level predictors of treatment 
response to vitamin D supplementation, including the 
status of vitamin D deficiency, MRI- detected bone marrow 
abnormalities and effusion- synovitis, and clinical signs of 
local inflammation. The protocol of this review is regis-
tered on the PROSPERO database (CRD42018107740).
study eligibility
This systematic review will include studies that meet the 
following inclusion criteria:
Type of studies
RCTs that have been published in journals and reported 
the efficacy of vitamin D in participants with knee OA 
will be included. Cross- over design will also be eligible 
and only the first phase data will be included in the 
analysis. Both individually randomised trials and cluster 
randomised trials will be eligible. Both open- labelled and 
blinded studies will be eligible. There will be no language 
or geographical restrictions applied to study selection.
Participants
Men and women who have a diagnosis of knee OA, 
either according to the American College of Rheuma-
tology criteria, or on the basis of detailed clinical and/or 
radiographic information, will be included. Studies with 
a subgroup of knee OA patients will also be included, 
provided that IPD can be collected separately for the OA 
subgroup. Although most patients with knee OA defined 
by the American College of Rheumatology are usually 
over 50 years of age, the disease can occur as early as 20 
years old, therefore studies with adults at 18 years of age 
and older will be included.
Interventions
Only studies investigating oral supplementation of 
vitamin D will be included. Vitamin D treatments admin-
istered subcutaneously, intraperitoneally or intravenously 
will not be included. Both ergocalciferol (vitamin D2) and 
cholecalciferol (vitamin D3) will be eligible, irrespective 
of preparations (tablet or capsule), dosage, regimen and 
length of treatment.
Comparators
Oral vitamin D supplementation will be compared with 
control treatment including placebo or usual conserva-
tive care (pain medication and/or exercise therapy if they 
are used in both treatment and control groups).
Outcomes
The minimum criterion for inclusion is reporting pain 
or physical function as either primary or secondary 
outcomes. There will be no restrictions on the duration 
of follow- up. Data on other outcomes (eg, patient’s global 
assessment, quality of life and adverse events) will be 
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analysed when feasible but will not be required for study 
selection.
Baseline assessments
As a minimum, included studies should have measured 
knee pain, physical function, serum levels of vitamin D at 
baseline, and included basic patient characteristics such 
as age, gender and body mass index (BMI).
literature search
A systematic literature search for articles published from 
1 January 1990 until 31 December 2019 will be performed 
by a trained review author (XJ) in the following electronic 
databases:
 ► Cochrane Central Register of Controlled Trials 
(CENTRAL).
 ► MEDLINE (Ovid).
 ► EMBASE.
A previous systematic review7 has showed that no 
major RCTs were conducted for vitamin D and OA by 
the year 1990, therefore we chose 1 January 1990 as the 
start date of the literature search. The search strategies 
used for each database are listed in online supplemen-
tary appendix 1. All retrieved articles will be exported to 
the reference manager EndNote, in which duplicates will 
be removed electronically and manually. The remaining 
records will be exported to an online systematic review 
management tool Covidence (Veritas Health Innovation, 
Melbourne, Australia) and the articles will be assessed 
for eligibility for inclusion. In addition to the electronic 
search, we will check the reference lists of included trials 
and previous systematic reviews to identify any trials that 
are not retrieved from the electronic search. Review 
authors and collaborating authors will be asked if they are 
aware of further relevant studies not yet included. We will 
also search the WHO International Clinical Trial Registra-
tion Platform Search Portal ( www. who. int/ trialsearch) to 
identify any relevant trials that are completed but did not 
published the results.
study selection
Two review authors (XJ, BA) will independently conduct 
study screening by assessing the article titles and abstracts. 
Full texts of the articles will be further assessed if the infor-
mation from the abstract suggests that a study is eligible 
for inclusion. When information contained in the full 
text is not sufficient to make a judgement on its eligibility, 
we will make efforts to contact the corresponding authors 
to obtain further details. If a corresponding author is 
not contactable after two email attempts and one phone 
call, the study will be deemed ineligible. Any disagree-
ment regarding the inclusion of a study will be discussed 
between the two review authors (XJ, BA). If no consensus 
can be reached, a third review author will be consulted 
(XW) to make a final decision.
Extraction of aggregate data
Study data extraction will be performed independently 
by two review authors (BA, XW). Discrepancies will be 
resolved by a third reviewer (XJ). We will extract the 
following study data from the included studies:
 ► General information: article title, bibliographic 
details, published language and funding source.
 ► Participants: inclusion criteria, exclusion criteria, 
number of participants in total and in each study arm, 
study settings and baseline participant characteristics 
(eg, age, gender, BMI).
 ► Intervention: type of vitamin D preparation, dose, 
regimen, treatment duration, type of control and 
co- interventions (if any).
 ► Outcomes: primary and secondary outcomes at 
the end of treatment and/or the end of follow- up. 
Number of withdrawals and loss to follow- up. Adverse 
events recorded.
 ► Data analysis: statistical models used for data anal-
ysis, confounding factors adjusted in the models and 
methods used for addressing missing values.
risk of bias assessment
The methodological quality of the included studies will 
be assessed using a modified version of the Cochrane’s 
risk of bias tool.23 The modified version includes all the 
seven domains of the original tool, but further separates 
performance bias assessment into ‘blinding of partici-
pants’ and ‘blinding of study personnel’, as well as pre- 
specifies other sources of bias as ‘balance in baseline 
covariates’, ‘treatment compliance’ and ‘timely outcome 
assessment’ (online supplementary appendix 2). Each 
domain will be scored as ‘low risk’, ‘high risk’ or ‘unclear’ 
according to the criteria described in the online supple-
mentay appendix 3. The overall rating of risk of bias is 
based on the number of domains with a ‘high- risk’ score. 
The overall rating is intended to inform readers of the 
risk of bias across individual studies and will not be used 
to weight the studies in the meta- analysis. Two review 
authors (XJ, XW) will independently evaluate the quality 
of an individual study. Any disagreement will be settled by 
further discussion until a consensus is reached between 
the two review authors.
IPd collection and transfer
The primary or corresponding authors of included 
trials will be invited to collaborate on the project and 
contribute their raw data. When we cannot reach a corre-
sponding author after sending two emails and making 
two telephone calls, we will contact the co- authors listed 
in the article. If none of the co- authors can be contacted, 
we will approach the institutes, in which the trial has been 
conducted. All data custodians will be asked to sign a 
data delivery agreement, which includes items regarding 
IPD delivery, obligations, ownership of data, terms and 
conditions of the use of the data, authorship and publi-
cations. If needed, the project coordinator (XJ) will visit 
the institutes of the data deliverers to retrieve the data 
and to sign the data delivery agreement on behalf of the 
OA Trial Bank (the detailed procedures of data delivery 
and an example of the data delivery agreement can be 
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found on the OA Trial Bank website https://www. oatri-
albank. com/ procedures/). De- identified datasets will be 
accepted in any electronic format (eg, SPSS, Stata, SAS, 
Excel) or in paper form, provided that variables and cate-
gories are adequately labelled within the dataset or within 
a separate codebook. The IPD files received by the coor-
dinator will be kept in their original version and saved 
on a secured password- protected server at Erasmus MC 
Medical University in Rotterdam. The datasets will not be 
used for any other research apart from that described in 
the license agreement.
To ensure the quality of the data, the coordinator will 
independently check for data consistency by comparing 
the summary statistics derived from the IPD received 
against the summary results reported in the published 
articles. In the case of differences, the project coordi-
nator will communicate with the data deliverer via email 
or teleconference to resolve the discrepancy.
Variables of interest
The following IPD variables will be obtained (where 
available):
Primary outcome variables
The primary outcomes for this meta- analysis will be pain 
and physical function at long- term follow- up (12 months 
or more). This definition of ‘long- term effect’ for knee 
OA treatment was used in previous systematic reviews of 
knee OA research.24 25
 ► Knee pain will be evaluated using visual analogue 
scale if available, otherwise the pain subscales of the 
Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC)26 or the Knee injury and 
Osteoarthritis Outcome Score (KOOS)27 will be 
used. The pain data will be converted into a 0–100 
common scale as recommended by the WOMAC 
manual.28
 ► Physical function will be evaluated using a validated 
instrument specific to knee OA, such as the phys-
ical function subscales of the WOMAC or the KOOS 
subscales. The scores will be standardised into a 0–100 
scale.
Secondary outcome variables
Secondary outcomes will include:
 ► Medium- term (more than 6 months but less than 12 
months) pain and physical function.
 ► Short- term (less than 6 months) pain and physical 
function.
 ► Patient global assessment at the end of study follow- up, 
as recommended by the Outcome Measures in Arthritis 
Clinical Trials - Osteoarthritis Research Society Inter-
national (OMERACT- OARSI) Initiative.29
 ► Quality of life evaluated using a validated instrument, 
such as EuroQol- 5D (EQ- 5D),30 osteoarthritis Knee 
and Hip Quality of Life,31 or original instrument used 
in the included studies.
 ► Adverse events if reported, including all major and 
minor events such as hypocalcaemia, fractures and 
depression.
Potential treatment effect moderators
If data are available, we will analyse potential treatment 
effect modification for the following variables measured 
at baseline:
 ► Radiographic stage of knee OA (mild/moderate or 
severe). Radiographic knee OA should be staged 
at baseline using either the Kellgren–Lawrence 
(KL)32 or Osteoarthritis Research Society Interna-
tional (OARSI) joint space narrowing (JSN) grading 
system.33 The results from the two grading systems 
have been shown to be highly correlated.34 Mild to 
moderate disease will be defined as a KL Score ≤3 or 
an OARSI JSN Score ≤2, and severe disease will be a 
KL score of 4 or an OARSI score of 3.
 ► Vitamin D level (deficiency, insufficiency or suffi-
ciency). Vitamin D deficiency is defined as serum levels 
of 25(OH)D less than 30 nmol/L at baseline. Insuffi-
ciency is defined as serum 25(OH)D levels from 30 
to <50 nmol/L. Serum 25(OH)D levels ≥50 nmol/L is 
considered as vitamin D sufficiency.35
 ► Presence of BMLs (yes or no). BMLs at the patella- 
femoral and femoro- tibial joints should be meas-
ured by MRI using a validated scoring system, such 
as Boston Leeds Osteoarthritis Knee Score,36 Whole- 
Organ MRI Score37 or Knee Osteoarthritis Scoring 
System.38
 ► Clinical signs of local inflammation or the presence 
of effusion- synovitis (yes or no). Clinical signs of local 
inflammation should be assessed by physical exam-
ination—tumour (swelling), dolor (pain), rubor 
(redness), calor (heat) and functio laesa (disturbance 
of function)—or by additional laboratory testing (eg, 
serum C reactive protein and erythrocyte sedimenta-
tion rate). Effusion- synovitis should be measured on 
either ultrasound or MRI.
 ► Presence of depressive symptoms or comorbid depres-
sion. Depressive symptoms are measured using a 
validated questionnaire, such as the Patient Health 
Questionnaire-939 and the Geriatric Depression 
Scale.40
data synthesis and statistical methods
All statistical analysis will be conducted using R V.3.5.0 
and RStudio (V.1.0.136, RStudio, Boston, Massachusetts, 
USA), with R extension package ‘metafor’ for the conven-
tional meta- analysis and two- stage IPD meta- analysis, and 
‘lme4’ for the one- stage IPD meta- analysis.
Conventional meta-analysis
An aggregate data meta- analysis, using a random- effects 
model based on the ‘Hartung- Knapp- Sidik- Jonkman’ 
method,41 will be performed to estimate the treatment 
effect of vitamin D over control. If an included study is 
a cluster RCT, results will be corrected using previously 
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established procedures.42 The results will be compared 
with the IPD meta- analysis findings as sensitivity analyses.
Heterogeneity will be assessed by inspecting the forest 
plots and tested by χ2 test. A result of p<0.10 will be defined 
as evidence of significant heterogeneity across studies. I2 
test will be used to estimate the extent of inconsistency 
across studies that is due to heterogeneity.43 A result of 
over 30% and 50% represents moderate and substantial 
heterogeneity, respectively. Sources of heterogeneity will 
be explored by excluding individual trials causing an I2 
score below 50%.
If 10 trials or more trials are available, we will use a Doi 
plot (normal quantile vs effect size plot) explore publica-
tion bias and ‘small- study effects’.44 Asymmetry in the Doi 
plot will be detected and quantified by the Luis Furuya- 
Kanamori (LFK) index. A value beyond ±1 will be deemed 
consistent with asymmetry, thus having considerable 
small- study effects.44
IPD meta-analysis
IPD from included trials will be recoded and formatted 
in a consistent way to permit re- analysis. A new variable 
will be created to indicate the trial in which the IPD are 
collected. The method used to handle missing data will 
depend on the mechanism causing the missingness. If 
no explanation is known for the reason of missing data, 
they will be assumed to be missing at random. We will 
use the R MICE package45 for multiple imputation, and 
the imputation model will include all available patient 
variables to help predict missing data for the variables of 
interest within each study dataset. The imputation proce-
dure will use 20 imputed datasets. A sensitivity analyses 
will be performed restricting to participants without 
missing data (complete case analysis).
Both the treatment effect of vitamin D supplementation 
and the effect of potential moderators will be studied in 
the IPD meta- analyses. The treatment effect of vitamin D 
will be measured using the mean difference in knee pain 
and physical function between treatment and control 
based on the intention- to- treat principle. The interaction 
between the treatment and a potential moderator will be 
used to identify the effect of the moderator. Interaction 
effects with p<0.05 will be considered statistically signif-
icant and 95% CIs of the effects will be provided. The 
IPD meta- analyses will be undertaken using both the one- 
stage and two- stage approaches. We will use the one- stage 
approach as the primary analysis to avoid assumptions 
of within- study normality and known within- study vari-
ance.46 We will and compare the results to the two- stage 
approach to assess consistency in a sensitivity analysis.
One-stage modelling
The one- stage mixed- effects IPD meta- analysis approach 
will take into account both study level and subject- level 
covariates. Subject- level covariates will be centred to the 
mean of the covariate in each trial to avoid ecological 
bias. Three multilevel regression models will be built, the 
first to examine the summary treatment effect (difference 
between vitamin D and control), the second to evaluate 
each of the mentioned moderators on treatment effect 
and the third to assess the true effect of one moderator 
independent of other moderators.
The first model will include outcome measure (eg, pain 
score at follow- up) as a dependent variable, treatment 
(vitamin D or control), baseline subject- level covariate 
(eg, pain score) and confounders (age, gender and BMI) 
as fixed- effect independent variables, adjusted for study 
identifier (random intercept). The partial regression 
coefficient of the treatment will be used to compare to 
the conventional meta- analysis.
The second model will further add the moderator of 
interest (eg, radiographic stage of the disease) and inter-
action term between the treatment and study- centred 
values of the moderator in the fixed effect of the first 
model. The regression coefficient of the interaction term 
will be used to quantify the impact of the moderator on 
treatment effect.
If there are two or more moderators that have a statis-
tically significant interaction with the treatment effect, 
these moderators will be incorporated in the third model. 
Multicollinearity between moderators will be tested 
before building the third model. A correlation coeffi-
cient r>0.80 will indicate that multiple collinearity exists 
between the two moderators, of which the one that has 
less measurement error will be included in the model.
Two-stage modelling
In the first stage, treatment effect and variance are 
derived from separate analysis in each study. An analysis 
of covariance model adjusted for baseline covariates (age, 
gender, BMI, as well as knee pain or function), will be 
used to obtain the treatment effect and variance within 
each study separately. The effect of a moderator and its 
variance within each study will be obtained by adding the 
interaction term between treatment effect and the moder-
ator into the model. In the second stage, the treatment 
effect and its variances obtained from the first stage will 
be pooled across studies using a random- effects model.41 
The result of this model is a summary estimate of the 
treatment effect of vitamin D versus control. The effect of 
a moderator will be calculated by pooling the regression 
coefficient and variance of the interaction term between 
the treatment and the moderator using a similar model. If 
two or more interaction terms are statistically significant, 
these moderators will be incorporated in a further model 
to evaluate the independent effect of these moderators.
Patient and public involvement
We do not directly include patient and public involve-
ment in this study, but the design of included RCTs may 
involve patients.
dIsCussIOn
Vitamin D supplementation may improve pain and func-
tion in patients with knee OA; however, the evidence 
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from observational studies and RCTs are controversial.7 18 
In a few existing RCTs in patients with symptomatic knee 
OA,14 16 17 small to modest improvement in knee pain and 
physical function were observed in participants receiving 
vitamin D supplementation, but the treatment response 
varies considerably and the effects were not statistically 
significant when compared with placebo. The broad 
variation in treatment response could be a result of the 
fact that knee OA is a highly heterogenous disease with 
multiple aetiologies.47 Vitamin D may therefore be more 
effective in a subset of patients with specific characteris-
tics than others. The purpose of the proposed IPD meta- 
analysis is to evaluate the treatment response of vitamin D 
supplementation on pain and physical function for knee 
OA in specific subsets of patients according to disease 
severity, vitamin D levels, presence of BMLs, inflamma-
tory signs and depressive symptoms, over both short- term 
and long- term follow- up.
Meta- analysis is considered by some to be the grand-
mother of ‘big data’48 and an integrated part of preci-
sion medicine.49 It is a cost- effective approach to identify 
potential moderators of treatment response at a patient 
level, which is not possible with subgroup analyses in a 
single trial or conventional meta- analysis with aggregate 
data.50 Subgroup analyses within individual trials are 
often underpowered to generate reliable findings. In 
contrast, IPD meta- analysis techniques increase the statis-
tical power of the study by combining individual observa-
tion data from multiple trials with the same treatment.22 
This offers greater precision in analysing moderators of 
treatment response and offers the potential to analyse 
a greater number of moderators. In conventional meta- 
analysis, meta- regression analysis may be used to examine 
differences in the types of patients enrolled in individual 
trials, but is potentially problematic. Meta- regression 
analysis may make incorrect inferences about individual 
characteristics based on aggregate baseline statistics 
reported in trial publications.51 This is also known as 
ecological fallacy,52 where the relationship between the 
effect estimate and average patient characteristics across 
trials may not be the same as the relationship within indi-
vidual trials.
Identifying different phenotypes of knee OA is currently 
a popular subject of research in the field. Different 
phenotyping strategies have been proposed based on risk 
factors from epidemiological studies,53 anatomical abnor-
malities on modern imaging54 or molecular abnormali-
ties related to pathological mechanisms.55 While there is 
currently no standardised classification system for knee 
OA phenotypes,5 we believe that disease phenotypes are 
most meaningful when they reflect differential treat-
ment effects. IPD meta- analysis provides an opportunity 
to assess the effect of treatments on subtypes or pheno-
types of patients with knee OA according to predefined 
set of characteristics. The current proposed IPD meta- 
analysis attempts to differentiate subgroups by identifying 
subtypes of patients that respond better to vitamin D 
supplementation on pain and physical function.
strengths and limitations
Several challenges may present when conducting an IPD 
meta- analysis. First, although IPD meta- analyses usually 
offer sufficient statistical power to examine moderators 
of treatment response, not all RCTs measure potential 
moderators of interest or measure them in the same way. 
This may limit the analysis to only exploring modera-
tors that have been collected across studies. The current 
protocol attempts to minimise this risk by including 
moderators that are commonly reported in OA research. 
In addition, there are expected barriers to accessing data, 
such as the authors of included trials not being able to 
be contacted, or the authors losing access to raw data 
or not choosing to collaborate, may introduce selection 
bias into the IPD meta- analysis. However, this could be 
examined in sensitivity analyses by comparing the results 
to the conventional meta- analysis or be addressed using 
frameworks that combine IPD and aggregate data in a 
meta- analysis.56
The benefits of using IPD meta- analysis techniques 
greatly outweigh the challenges of using this intensive 
method. Previous RCTs and systematic reviews have not 
had sufficient power to thoroughly examine the differ-
ential treatment response of vitamin D supplementation 
in different subsets of patients with knee OA. The results 
of this project have a high potential to provide important 
evidence to guide subgroup- specific treatment decisions 
in clinical practice to improve therapeutic effectiveness.
status of project
Currently, literature search in the electronic databases 
has been completed.
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